Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 18 participants in total — 9 people who used a nasal spray and 9 who used nasal drops. All 18 participants completed the study, with no one dropping out. The trial was measuring how well each delivery method — spray versus drops — spread a contrast liquid (a substance that shows up on scans) throughout different areas inside the nasal cavity. To do this, researchers used CT scans and divided each person's nasal cavity into 21 sections on each side (42 sections total), scoring each section as either reached (1) or not reached (0) by the spray or drops. The reported data shows a series of distribution scores for the nasal spray and nasal drops across different measurements of the nasal cavity. For the nasal spray, the reported scores were 18, 16, 0, 12, 16, and 15. For the nasal drops, the corresponding reported scores were 17, 17, 6, 4, 0, and 6. These numbers reflect how many nasal cavity sections (out of a possible 42) showed the presence of the contrast substance in each measurement recorded. The reported data does not include labels explaining what specific nasal sub-regions each pair of scores refers to, so a detailed breakdown by location cannot be described here. It is worth noting that this was a small study with only 9 participants in each group, and the results as submitted describe distribution patterns only — the trial was not measuring whether either method treated or improved any condition. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 16360518) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Chronic Rhinosinusitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are an adult who is able to carry out normal daily activities on your own
Who may not be able to join:
- You currently have signs or symptoms of a sinus infection or ongoing sinus problems
- You have had surgery on your sinuses in the past
- You have a deviated septum (a crooked wall inside your nose) that causes you symptoms
- You currently have active seasonal allergies
- You have an allergy to contrast dye (a special liquid sometimes used in scans)
- You have a history of nasal polyps (small growths inside the nose)
- You are currently pregnant or breastfeeding
- You have neck or back problems that would stop you from kneeling on the floor and crouching over
- You are currently taking the medications metformin or amiodarone
- You are a student or staff member who is directly supervised by the researchers running this trial
- You have a condition that affects your thinking, memory, or understanding
- You have a terminal illness
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To Measure the Distribution of Nasal Sprays and Drops.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.